The significant downward revision in EPS guidance for 2024 by Bristol Myers Squibb is a strong indicator of the negative impact of recent transactions on the company's financial outlook. This adjustment is likely to lead to negative investor sentiment in the short term, as it represents a substantial decrease from previous expectations. The closeness of the revised guidance to the consensus estimate suggests that the market may have already been anticipating some level of adjustment, but the magnitude of this change is still likely to surprise investors.